Profit Warnings & Pricing Scrutiny

MarcusWelcome to the Access Brief — your daily briefing on what's moving in HEOR, HTA, and market access. I'm Marcus, health economist, and it's great to have you with us today.

SaraAnd I'm Sara, market access strategy. Always good to be here — and I'll say, I've had today's topics circled since this morning. The system pressures are really mounting.

MarcusSame here. We're looking at HCA's profit warning — what it signals about uncompensated care volumes in US hospitals. Then subcutaneous Leqembi's approval — how that changes Alzheimer's evidence generation. The FTC's insulin pricing settlement with CVS Caremark — and ICER expanding scientific advice into early development.

SaraThat second one is particularly interesting — the HEOR implications of a subcutaneous formulation for a high-cost, high-uncertainty therapy. The budget impact question there is one the field hasn't fully worked out yet.

MarcusExactly. Let's get into it.

MarcusStarting with HCA's profit warning — they're citing rising uninsured patient volumes and uncompensated care costs. This isn't just one operator; it's a bellwether for broader US hospital system stress. What strikes me is how this connects to commercial payers' coverage decisions.

SaraThat's fair, though I think payers would see this differently. When hospitals face margin pressure, they often push back harder on reimbursement rates. We're already seeing increased prior authorization for high-cost drugs in these markets. The access gap isn't just clinical anymore — it's financial.

MarcusThat connects to something I keep coming back to: the sustainability argument. If hospitals absorb uncompensated care, it eventually ripples back to premiums. But the part that gives me pause is whether this accelerates value-based contracting for hospital services.

SaraI'd push back slightly on that. The immediate pressure is on unit economics, not system redesign. What I'm seeing is payers tightening formularies for drugs with high hospital administration costs. The budget impact is real, and opportunity cost is starting to dominate coverage committees.

MarcusWhat's striking here is how this could reshape HEOR evidence needs. We might need more hospital-level cost data in submissions, not just patient-level outcomes.

SaraAbsolutely. And from the payer side, we'll be watching how this affects risk-sharing agreements. If hospitals are under financial stress, they might be more open to outcomes-based contracts for drugs that reduce admissions.

MarcusThat's a forward-looking angle. Let's shift to subcutaneous Leqembi — the FDA approval. This changes the treatment landscape significantly for Alzheimer's.

SaraI wonder if that's the full picture though. The oral formulation had adherence challenges, but subcutaneous doesn't solve the underlying value proposition problem. Payers will still question whether the marginal improvement in administration justifies the price tag. The budget impact question remains unresolved.

MarcusThat's one read — I'd frame it slightly differently. The route of administration enables broader real-world evidence generation. We'll now see more consistent dosing, which could provide clearer long-term outcomes data. That's crucial for HTA bodies.

SaraThe part that gives me pause is the timing. We're entering a phase where multiple Alzheimer's therapies are coming to market. The opportunity cost for payers is enormous. They'll need comparative effectiveness data, not just single-arm studies.

MarcusWhat strikes me is how this accelerates the need for RWE in neurodegenerative diseases. Traditional RCTs won't capture real-world adherence and persistence. This could be a watershed moment for decentralized trials in HEOR.

SaraAnd from the payer perspective, we'll be watching how this affects cost-effectiveness thresholds. If real-world data shows better outcomes than RCTs, that could shift value assessments. But if adherence is still suboptimal, the value proposition unravels.

MarcusLet's move to the FTC settlement with CVS Caremark over insulin pricing. The allegations involve anticompetitive practices in pharmacy benefit management.

SaraThis is one of those stories where the implications go beyond insulin. The FTC's action signals increased scrutiny of PBM rebate structures. For market access teams, this means more transparency pressure on net prices. The opportunity cost question here is about what gets squeezed when rebates are reallocated.

MarcusThat's fair — though I think the innovation angle matters too. If PBMs face more regulatory constraints, how does that affect incentives for manufacturers to invest in novel therapies? The R&D investment side can't be ignored.

SaraI'd frame it slightly differently: this could accelerate the shift from gross-to-net pricing. Payers are already moving toward value-based contracting, and this settlement might push that faster. What matters for us is how manufacturers position drugs in a more transparent pricing environment.

MarcusThe part that gives me pause is the precedent. If the FTC wins here, it opens the door for similar actions in other therapeutic areas. That could fundamentally change how we approach pricing strategy.

SaraExactly. And from the payer side, we'll be watching how this affects formulary negotiations. If rebates become more transparent, it might create space for drugs with strong clinical value to gain market access. The budget impact equation is shifting.

MarcusFinally, ICER expanding scientific advice into early development phases. This is significant for evidence generation.

SaraWhat strikes me about this is the timing. ICER is now engaging at Phase I/II, which could reshape clinical trial design. For market access, this means earlier evidence generation — but also earlier risk of misaligned endpoints. The opportunity cost is in resource allocation for development teams.

MarcusI wonder if that's the full picture though. This could actually de-risk late-stage development by ensuring trial endpoints meet HTA requirements. That's good for both innovation and access. The R&D investment side benefits from reduced late-stage failures.

SaraThat's one read — but payers might see it differently. Earlier engagement could lead to more conservative trial designs that prioritize cost-effectiveness over breakthrough potential. We might see more trials with surrogate endpoints rather than hard clinical outcomes.

MarcusThe part that gives me pause is how this affects global harmonization. If ICER sets expectations early, will other HTA bodies follow? That could streamline evidence generation across markets.

SaraAnd from the payer perspective, we'll be watching how this affects the evidence review timeline. Earlier scientific advice might compress the assessment period, which could accelerate access for high-value drugs. But it also raises questions about the quality of early data.

MarcusA lot to think about today. I'll be watching how the HCA situation impacts commercial payer coverage policies for high-cost drugs.

SaraSame — and for me the thread running through today is the tension between system sustainability and innovation. These stories show that both sides are feeling pressure. Worth sitting with.

SaraThanks so much for listening — really glad you're here with us.

MarcusWe'll be back tomorrow. Show notes and transcripts at outcomes-analytica.no. See you then.

SaraThanks for listening — see you tomorrow.

MarcusBack tomorrow on Access Brief. Show notes at outcomes-analytica.no.